Free Trial
NASDAQ:GLTO

Galecto Q2 2025 Earnings Report

Galecto logo
$3.38 +0.12 (+3.68%)
Closing price 08/8/2025 02:48 PM Eastern
Extended Trading
$3.40 +0.02 (+0.74%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galecto EPS Results

Actual EPS
-$2.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Galecto Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galecto Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Galecto's Q3 2025 earnings is scheduled for Monday, August 11, 2025

Galecto Earnings Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
See More Galecto Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galecto? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galecto and other key companies, straight to your email.

About Galecto

Galecto (NASDAQ:GLTO), a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

View Galecto Profile

More Earnings Resources from MarketBeat